Welcome to our dedicated page for WINDTREE THERAPEUTICS /DE/ SEC filings (Ticker: WINT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on WINDTREE THERAPEUTICS /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into WINDTREE THERAPEUTICS /DE/'s regulatory disclosures and financial reporting.
Windtree Therapeutics (NASDAQ:WINT) filed an 8-K disclosing three material events dated June 24-25, 2025.
- $150,000 raised via two 14% convertible promissory notes (12-month maturity, $0.587 conversion price) plus warrants covering 75% of each investment.
- Seller TBB Crescent Park Drive LLC terminated a Texas real-estate purchase; it demands release of $3 million earnest money paid by Way Maker and Windtree, which the company is disputing.
- CFO Jamie McAndrew resigned effective June 25; CEO Jed Latkin will serve as interim principal financial officer.
The notes and warrants were issued under Rule 506(b) exemptions and proceeds will fund operations. The property dispute could create a cash outflow materially larger than the new financing, and management turnover raises governance concerns.
Windtree Therapeutics (WINT) has received a Nasdaq deficiency notice on June 18, 2025, for failing to maintain the minimum bid price requirement of $1.00 per share over the last 30 consecutive business days.
Unlike standard cases where companies receive a 180-day compliance period, Windtree faces immediate delisting risk due to two key factors:
- The company is under a Discretionary Panel Monitor until March 20, 2026
- It has conducted two reverse stock splits in the past two years with a cumulative ratio exceeding 250:1, making it ineligible for the standard compliance period
Windtree plans to request a hearing before the Nasdaq Hearings Panel by June 25, 2025, which will automatically stay any suspension/delisting action. The company's stock continues trading on Nasdaq Capital Market under "WINT" symbol, though there is no guarantee of maintaining the listing or regaining compliance.